Copyright © 2002 by the European Society of Cardiology.
Hotline Editorial
Sudden unexpected cardiac death
London, U.K
References
- Lawrie DM, Higgins MR, Godman MJ, Oliver MF, Julian DG, Donald KW. Ventricular fibrillation complicating myocardial infarction. Lancet. 1968;ii:523528
- Myerberg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119:11871197
[Abstract/Free Full Text] - Cobb LA, Fahrenbruch CE, Walsh TR. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999;281:11821188
[Abstract/Free Full Text] - Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med. 2002;112:519527[CrossRef][Web of Science][Medline]
- Kurien VA, Oliver MF. A metabolic cause for arrhythmias during acute myocardial hypoxia. Lancet. 1970;ii:813815
- Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Am J Cardiol. 1975;36:938953[CrossRef][Web of Science][Medline]
- Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart. Ann Rev Physiol. 1974;36:413459[CrossRef][Web of Science][Medline]
- Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet. 1994;343:155158[CrossRef][Web of Science][Medline]
- Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure
-3 polyunsaturated fatty acids in dogs. Circulation. 1999;99:24522457[Abstract/Free Full Text] - Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J Supplements. 2001;3:D98D105[Abstract]
- Albert CM, Campos H, Stampfer MJ. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:11131118
[Abstract/Free Full Text] - Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med. 2002;112:305311[CrossRef][Web of Science][Medline]
- Lopashuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol. 1998;30:A112
- Bagger JP, Botker HE, Thomassen A, Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther. 1997;11:479484[CrossRef][Web of Science][Medline]
- Lancet. 1999;354:447455[CrossRef][Web of Science][Medline]
- Apstein CS, Opie LH. Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drugs Ther. 1999;13:185189[CrossRef][Web of Science][Medline]
- Diaz R, Paolasso EC, Piegas LS. Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium pilot trial. Circulation. 1999;98:227234
- Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:15121515
[Abstract/Free Full Text] - Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol. 1998;82:14K17K[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||